Gestala Highlights Early Funding Momentum and Hiring Drive in Ultrasound-Based BCI

According to a recent LinkedIn post from Gestala, the Chengdu-based NeuroAI and brain-computer interface startup is emphasizing its rapid early-stage development and hiring plans. The post notes that Gestala, described as China’s first ultrasound-based BCI pioneer since its January 1 launch, has attracted approximately ¥150M (over $20M) in angel funding within two months.

The company’s LinkedIn post highlights an ambition to build its BCI and NeuroAI platform from Chengdu, citing advantages such as proximity to West China Hospital, a growing biotech and hardware cluster, and the city’s broader livability. For investors, this positioning suggests a strategy that leverages regional medical and industrial ecosystems while potentially benefiting from lower operating costs compared with first-tier Chinese cities.

The post outlines hiring expectations of growing to more than 40 employees by year-end, with a focus on scientific research, engineering and, in particular, artificial intelligence roles in multimodal models and machine learning. This hiring emphasis may indicate that Gestala is still in a technology-development phase, prioritizing R&D capacity over immediate commercialization, which could lengthen the path to revenue but deepen its intellectual property base.

As shared in the post, Gestala frames Chengdu as a global innovation center, citing GDP above ¥2.47 trillion and strong international connectivity via two airports and extensive flight routes. If these regional macro factors continue, they could support talent attraction and international collaboration, which are important for scaling deep-tech ventures in BCI and AI.

For investors tracking the BCI and NeuroAI segments, the content suggests an early-stage company with substantial seed capital and aggressive talent acquisition plans in a specialized niche. While no specific product timelines, regulatory milestones or revenue targets are mentioned, the scale of angel funding and focus on advanced AI and neuroscience roles may point to high-risk, high-reward potential typical of frontier neurotechnology startups.